Negative Inotropic Effect of Rapamycin on Isolated Human Cardiomyocytes

Rapamycin is an increasingly important immunosuppressive drug and reduces restenosis after coronary stenting, but its effects on cardiac contractility are largely unknown. We investigated the acute inotropic effects of rapamycin on isolated human cardiomyocytes. Cardiomyocytes were enzymatically isolated from right atrial appendages obtained during routine coronary artery bypass surgery. Cell morphology was examined by confocal microscopy. Cell contraction was recorded after electrical stimulation. Rapamycin elicited a concentration-dependent decrease in fractional cell shortening ranging from 14.3 ± 2.6% at 10−8 M rapamycin to 26.4 ± 4.2% at 10−5 M. Rapamycin also caused a concentration-dependent decrease in diastolic cell length. Contractile performance of isolated cardiomyocytes was well preserved, as evidenced by the profound positive inotropic effects of high extracellular calcium concentration and the β-adrenoreceptor agonist isoproterenol. The acute negative inotropic effect of rapamycin on human cardiomyocytes might be due to altered calcium homeostasis through the binding of rapamycin to FKBP12.6 and its regulatory function on the ryanodine receptor, with increased calcium leakage from the sarcoplasmic reticulum.

[1]  B. Gersh Coronary Collateral Function Long After Drug-Eluting Stent Implantation , 2008 .

[2]  William Wijns,et al.  Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. , 2007, Circulation.

[3]  H. Möllmann,et al.  Contractile effects of angiotensin and endothelin in failing and non-failing human hearts. , 2007, International journal of cardiology.

[4]  G. Montalescot,et al.  Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.

[5]  Adnan Kastrati,et al.  Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. , 2006, Journal of the American College of Cardiology.

[6]  A. Ceylan-isik,et al.  Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. , 2005, The Journal of endocrinology.

[7]  M. Sata,et al.  The role of circulating precursors in vascular repair and lesion formation , 2005, Journal of cellular and molecular medicine.

[8]  B. Kahan Sirolimus-based immunosuppression: present state of the art. , 2004, Journal of nephrology.

[9]  J. Schaper,et al.  Tissue-Specific Patterns of Gap Junctions in Adult Rat Atrial and Ventricular Cardiomyocytes In Vivo and In Vitro , 2001, Circulation research.

[10]  Godfrey L. Smith,et al.  Overexpression of FK506-Binding Protein FKBP12.6 in Cardiomyocytes Reduces Ryanodine Receptor–Mediated Ca2+ Leak From the Sarcoplasmic Reticulum and Increases Contractility , 2001, Circulation research.

[11]  J. Zimmerman,et al.  Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. , 2000, Clinical therapeutics.

[12]  S. Fleischer,et al.  Selective Binding of FKBP12.6 by the Cardiac Ryanodine Receptor* , 1996, The Journal of Biological Chemistry.

[13]  A. Marks,et al.  Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein , 1994, Cell.

[14]  William Wijns,et al.  A Cause for Concern , 2007 .